Short Term Rating on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (RARE) : Zacks Investment Research ranks Ultragenyx Pharmaceutical (RARE) as 3, which is a Hold recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 14 research analysts is 1.21, which indicates as a Strong Buy.

Ultragenyx Pharmaceutical (RARE) : The consensus price target for Ultragenyx Pharmaceutical (RARE) is $95.23 for the short term with a standard deviation of $16.53. The most optimist securities analyst among the 13 who monitor the stock believes that the stock can reach $125, however, the pessimist price target for the company is $70.

For the current week, the company shares have a recommendation consensus of Buy.


Ultragenyx Pharmaceutical (NASDAQ:RARE): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $54.43 and $53.32 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $57.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $54.40, notching a gain of 2.87% for the day. The total traded volume was 1,042,849 . The stock had closed at $52.88 on the previous day.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.